Treatment of pulmonary arterial hypertension
M Humbert, O Sitbon… - New England Journal of …, 2004 - Mass Medical Soc
Pulmonary arterial hypertension, which is characterized by vascular proliferation and
remodeling of small pulmonary vessels, leads to a progressive increase in pulmonary vascular …
remodeling of small pulmonary vessels, leads to a progressive increase in pulmonary vascular …
Diagnosis and differential assessment of pulmonary arterial hypertension
RJ Barst, M McGoon, A Torbicki, O Sitbon… - Journal of the American …, 2004 - jacc.org
… Consistent observations in PAH are reduced peak Vo 2 , peak work rate, the ratio of Vo 2
increase to work rate increase, anaerobic threshold, peak oxygen pulse, and increased Ve-Vco …
increase to work rate increase, anaerobic threshold, peak oxygen pulse, and increased Ve-Vco …
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary …
…, G Rådegran, G Simonneau, O Sitbon… - European heart …, 2022 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …
clinical conditions and may be associated with a variety of cardiovascular and respiratory …
Pulmonary arterial hypertension in France: results from a national registry
M Humbert, O Sitbon, A Chaouat… - American journal of …, 2006 - atsjournals.org
Rationale: Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend
is for management in designated centers with multidisciplinary teams working in a shared-…
is for management in designated centers with multidisciplinary teams working in a shared-…
[HTML][HTML] Inhaled iloprost for severe pulmonary hypertension
…, MM Hoeper, J Behr, J Winkler, O Sitbon… - … England Journal of …, 2002 - Mass Medical Soc
Background Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …
[HTML][HTML] Macitentan and morbidity and mortality in pulmonary arterial hypertension
…, L Perchenet, BKS Sastry, O Sitbon… - … England Journal of …, 2013 - Mass Medical Soc
Background Current therapies for pulmonary arterial hypertension have been adopted on the
basis of short-term trials with exercise capacity as the primary end point. We assessed the …
basis of short-term trials with exercise capacity as the primary end point. We assessed the …
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
RN Channick, G Simonneau, O Sitbon, IM Robbins… - The Lancet, 2001 - thelancet.com
Background Endothelin 1, a powerful endogenous vasoconstrictor and mitogen, might be a
cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual …
cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual …
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
Objectives : We sought to determine the factors associated with long-term survival in patients
with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion. …
with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion. …
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
… measurements included mean right atrial pressure, mean PAP, mean PWP, cardiac output
determined by the thermodilution technique, and mixed venous oxygen saturation (Svo 2 ). …
determined by the thermodilution technique, and mixed venous oxygen saturation (Svo 2 ). …
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
M Humbert, O Sitbon, A Chaouat, M Bertocchi… - Circulation, 2010 - Am Heart Assoc
Background— Novel therapies have recently become available for pulmonary arterial
hypertension. We conducted a study to characterize mortality in a multicenter prospective cohort of …
hypertension. We conducted a study to characterize mortality in a multicenter prospective cohort of …